JP2018520650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520650A5 JP2018520650A5 JP2017560535A JP2017560535A JP2018520650A5 JP 2018520650 A5 JP2018520650 A5 JP 2018520650A5 JP 2017560535 A JP2017560535 A JP 2017560535A JP 2017560535 A JP2017560535 A JP 2017560535A JP 2018520650 A5 JP2018520650 A5 JP 2018520650A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cancer
- specific
- bispecific
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022077013A JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1508729.9 | 2015-05-21 | ||
| GBGB1508729.9A GB201508729D0 (en) | 2015-05-21 | 2015-05-21 | Binding molecules |
| GB1514994.1 | 2015-08-24 | ||
| GBGB1514994.1A GB201514994D0 (en) | 2015-08-24 | 2015-08-24 | Bispecific polypeptide |
| GB201605450 | 2016-03-31 | ||
| GB1605450.4 | 2016-03-31 | ||
| PCT/EP2016/061420 WO2016185016A1 (en) | 2015-05-21 | 2016-05-20 | Novel polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077013A Division JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018520650A JP2018520650A (ja) | 2018-08-02 |
| JP2018520650A5 true JP2018520650A5 (enExample) | 2019-06-20 |
Family
ID=56026872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560535A Pending JP2018520650A (ja) | 2015-05-21 | 2016-05-20 | 新規のポリペプチド |
| JP2022077013A Active JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022077013A Active JP7419434B2 (ja) | 2015-05-21 | 2022-05-09 | 新規のポリペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11008396B2 (enExample) |
| EP (2) | EP3298045A1 (enExample) |
| JP (2) | JP2018520650A (enExample) |
| KR (1) | KR102712820B1 (enExample) |
| CN (2) | CN114181309B (enExample) |
| AU (1) | AU2016265447B2 (enExample) |
| BR (1) | BR112017024770A2 (enExample) |
| IL (1) | IL255767B2 (enExample) |
| MX (1) | MX2017014699A (enExample) |
| RU (1) | RU2017142008A (enExample) |
| WO (1) | WO2016185016A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016303472B2 (en) | 2015-07-31 | 2020-08-27 | Immunewalk Therapeutics, Inc. | Motile sperm domain containing protein 2 and inflammation |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| WO2017182672A1 (en) | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| EP3858858A1 (en) | 2016-06-20 | 2021-08-04 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
| BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
| US12544236B2 (en) | 2016-06-29 | 2026-02-10 | Globus Medical Inc. | Expandable fusion device and method of installation thereof |
| GB201611530D0 (en) * | 2016-07-01 | 2016-08-17 | Alligator Bioscience Ab | Novel polypeptides |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN109983033B (zh) | 2016-09-23 | 2023-10-31 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| GB201619652D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel polypeptides |
| BR112019012328A2 (pt) * | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anticorpos anti-ox40 e seus usos |
| JP7132232B2 (ja) * | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| BR112019023097A2 (pt) * | 2017-05-02 | 2020-07-28 | Alligator Bioscience Ab | anticorpo biespecífico contra ox40 e ctla-4 |
| AU2017414149B2 (en) | 2017-05-19 | 2025-05-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| US11312783B2 (en) * | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
| IL272103B2 (en) * | 2017-07-20 | 2024-10-01 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer |
| IL272159B2 (en) | 2017-08-04 | 2026-03-01 | Genmab As | PD-L1 and CD137 binding agents and their use |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| JP7489316B2 (ja) | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019175806A1 (en) * | 2018-03-13 | 2019-09-19 | Vascular Biogenics Ltd. | Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules |
| CA3103040A1 (en) | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| AU2019301206B2 (en) * | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| WO2020127374A2 (en) * | 2018-12-17 | 2020-06-25 | Alligator Bioscience Ab | Novel polypeptides |
| EP3902833A2 (en) | 2018-12-26 | 2021-11-03 | City of Hope | Activatable masked anti-ctla4 binding proteins |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| MX2022001882A (es) * | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| CN114555638B (zh) * | 2019-10-11 | 2023-08-22 | 南京维立志博生物科技有限公司 | 结合4-1bb的抗体及其用途 |
| CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
| WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| KR20220140500A (ko) | 2020-01-13 | 2022-10-18 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | 약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물 |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| JP2023547026A (ja) | 2020-09-10 | 2023-11-09 | バスキュラー バイオジェニックス リミテッド | 運動精子ドメイン含有タンパク質２抗体およびその使用法 |
| CA3196726A1 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| JP2024508746A (ja) * | 2021-02-17 | 2024-02-28 | アプティーボ リサーチ アンド デベロップメント エルエルシー | ４－１ｂｂおよびｏｘ４０結合タンパク質を含む組成物および使用方法 |
| JP2024519964A (ja) | 2021-05-21 | 2024-05-21 | アプティーボ リサーチ アンド デベロップメント エルエルシー | タンパク質治療薬のための投薬レジメン |
| CA3252619A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-CD28 and anti-PSMA antibodies |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| KR20250173599A (ko) * | 2023-03-14 | 2025-12-10 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| KR100452954B1 (ko) * | 2002-02-26 | 2004-10-14 | 주식회사 엘지생명과학 | 가변영역 아미노산 치환을 통한 인간 4-1비비분자에 대한결합 특이성이 증가된 변형 인간화 항체의 제조방법 |
| AU2004210088A1 (en) * | 2003-02-06 | 2004-08-19 | Micromet Ag | Trimeric polypeptide construct to induce an enduring T cell response |
| CN1894413A (zh) * | 2003-03-26 | 2007-01-10 | 特鲁比昂药品公司 | 识别cd3或4－1bb的抗体或基因介导的肿瘤反应性淋巴细胞活化 |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| EP2399935A3 (en) | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| CN104497143B (zh) | 2007-03-29 | 2020-08-25 | 健玛保 | 双特异性抗体及其制造方法 |
| KR101577843B1 (ko) * | 2007-12-14 | 2015-12-16 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ｏｘ４０ 수용체에 대한 결합 분자 |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| SG10201912092VA (en) * | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| WO2014043708A1 (en) * | 2012-09-17 | 2014-03-20 | Traber Peter G | Method for enhancing specific immunotherapies in cancer treatment |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| WO2015095423A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| AU2016219772A1 (en) * | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
-
2016
- 2016-05-20 AU AU2016265447A patent/AU2016265447B2/en active Active
- 2016-05-20 RU RU2017142008A patent/RU2017142008A/ru unknown
- 2016-05-20 MX MX2017014699A patent/MX2017014699A/es unknown
- 2016-05-20 US US15/567,163 patent/US11008396B2/en not_active Expired - Fee Related
- 2016-05-20 WO PCT/EP2016/061420 patent/WO2016185016A1/en not_active Ceased
- 2016-05-20 CN CN202111495490.3A patent/CN114181309B/zh active Active
- 2016-05-20 CN CN201680028916.5A patent/CN107709367A/zh active Pending
- 2016-05-20 IL IL255767A patent/IL255767B2/en unknown
- 2016-05-20 KR KR1020177033709A patent/KR102712820B1/ko active Active
- 2016-05-20 EP EP16724036.5A patent/EP3298045A1/en not_active Withdrawn
- 2016-05-20 EP EP21202262.8A patent/EP3988577A1/en active Pending
- 2016-05-20 BR BR112017024770A patent/BR112017024770A2/pt not_active IP Right Cessation
- 2016-05-20 JP JP2017560535A patent/JP2018520650A/ja active Pending
-
2020
- 2020-02-03 US US16/780,401 patent/US10774150B2/en not_active Expired - Fee Related
-
2021
- 2021-04-13 US US17/229,130 patent/US11780928B2/en active Active
-
2022
- 2022-05-09 JP JP2022077013A patent/JP7419434B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017142008A (ru) | Новые полипептиды | |
| JP2016529215A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| HRP20211333T1 (hr) | Molekule za vezanje pd-1 i lag-3 i postupci za njihovu uporabu | |
| JP2022515318A5 (enExample) | ||
| JP2019500891A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| IL273424B2 (en) | Novel bispecific cd3/cd19 polypeptide complexes | |
| JP2018503380A5 (enExample) | ||
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2019500892A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020502271A5 (enExample) | ||
| RU2019138067A (ru) | Биспецифическое антитело против ox40 и ctla-4 | |
| JP2010531140A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP2016537966A5 (enExample) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2014158469A5 (enExample) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2013527761A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2016512223A5 (enExample) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof |